SI-BONE IncSIBN
SIBN
About: SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Employees: 349
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,276% more call options, than puts
Call options by funds: $908K | Put options by funds: $66K
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
53% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 38
10% more funds holding
Funds holding: 143 [Q4 2024] → 158 (+15) [Q1 2025]
2% more capital invested
Capital invested by funds: $558M [Q4 2024] → $567M (+$9.28M) [Q1 2025]
0.37% more ownership
Funds ownership: 94.91% [Q4 2024] → 95.28% (+0.37%) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
26%
upside
Avg. target
$24
36%
upside
High target
$25
44%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Samuel Brodovsky | 26%upside $22 | Buy Maintained | 6 May 2025 |
Cantor Fitzgerald Ross Osborn | 44%upside $25 | Overweight Reiterated | 6 May 2025 |
Needham David Saxon | 38%upside $24 | Buy Reiterated | 6 May 2025 |
Financial journalist opinion
Based on 4 articles about SIBN published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
Neutral
GlobeNewsWire
1 week ago
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA.
Neutral
GlobeNewsWire
2 weeks ago
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
MarketBeat
1 month ago
4 Recent Earnings Winners Riding Fresh Momentum in May
The market turbulence in 2025 has sent stocks zig-zagging up and down. Despite the unavoidable impact of political developments on share price performance, some companies have seen major gains based on a more traditional driver of motion: strong earnings reports.
Positive
Zacks Investment Research
1 month ago
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time.
Neutral
Seeking Alpha
1 month ago
SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Saqib Iqbal - VP, FP&A, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America David Turkaly - Citizens JMP Young Li - Jefferies Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Operator Good afternoon. And welcome to SI-BONE's First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
1 month ago
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
Charts implemented using Lightweight Charts™